<DOC>
	<DOCNO>NCT00097747</DOCNO>
	<brief_summary>The purpose study evaluate safety , pharmacokinetics ( PK ) , minimum pharmacologically active dose peginesatide Healthy Volunteers .</brief_summary>
	<brief_title>Safety Pharmacokinetics Single Intravenous Doses Peginesatide Healthy Volunteers</brief_title>
	<detailed_description>This Phase 1 , double-blind , placebo-controlled trial peginesatide , erythropoiesis stimulating agent , approximately 7 treatment cohort 7 healthy volunteer participant per cohort . In cohort 7 participant , ratio 5:2 participant randomly assign receive single dose peginesatide placebo , respectively , administer intravenous infusion . Planned peginesatide dose level escalate cohort . The study conduct single clinical center .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<criteria>Main eligibility criterion : Participant healthy male , age ≥ 18 year ≤ 40 year , body mass index ( BMI ) ≥ 18 ≤ 30 kilogram per square meter ( kg/m^2 ) , weight ≥ 50 ≤ 95 kilogram ( kg ) Participant hemoglobin ≤ 16 gram per deciliter ( g/dL ) time study entry Participant normal iron store</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>anemia</keyword>
	<keyword>chronic kidney disease</keyword>
	<keyword>CKD</keyword>
	<keyword>chronic renal failure</keyword>
	<keyword>CRF</keyword>
	<keyword>erythropoietin</keyword>
	<keyword>EPO</keyword>
	<keyword>erythropoiesis stimulating agent</keyword>
	<keyword>ESA</keyword>
	<keyword>Hematide™</keyword>
	<keyword>hemoglobin</keyword>
	<keyword>Hb</keyword>
	<keyword>Hgb</keyword>
	<keyword>Omontys</keyword>
	<keyword>peginesatide</keyword>
	<keyword>red blood cell</keyword>
	<keyword>red blood cell production</keyword>
</DOC>